Posted by Michael Wonder on 20 Jan 2023
Opiant Pharmaceuticals announces FDA acceptance and priority review of NDA for OPNT003, nasal nalmefene, for opioid overdose
19 January 2023 - FDA sets PDUFA date of 22 May 2023.
Opiant Pharmaceuticals today announced that the US FDA has accepted for review the new drug application for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.
